GlassScriptPhysician profile
Princy S Daniel
NPI 1184189292
$9,717.93
in general payments reported to CMS, 2019-2025
18 companies · $3,131 in 2025
The $3,131 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $851 · 2022: $1,776 · 2023: $1,525 · 2024: $2,435 · 2025: $3,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,851 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,851.28 |
| Education | $239.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,716.76 | 2021-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,878.50 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,199.54 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $582.04 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $484.93 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $392.38 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $271.82 | 2021-2024 | Dificid, Zerbaxa, Prevymis |
| Qol Medical, LLC | $269.69 | 2024-2025 | Sucraid, Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.94 | 2023-2024 | Cyltezo |
| Celltrion USA INC. | $184.54 | 2024-2025 | Vegzelma, Zymfentra |
| Daiichi Sankyo INC. | $133.94 | 2021-2022 | |
| Celgene Corporation | $113.04 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $89.64 | 2025 | Vowst |
| Integra Lifesciences Corporation | $71.09 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Janssen Scientific Affairs, LLC | $50.95 | 2024-2025 | Tremfya, Stelara |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $24.73 | 2023 | Rebyota |
| Organon LLC | $23.65 | 2021 | |
| Redhill Biopharma INC. | $18.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Princy Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.